Samrotamab
Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric antibody targeting LRRC15. Samrotamab markedly reduces bladder cancer cells viability and inhibits clonogenic growth, migratory and invasive capabilities. Samrotamab significantly increases LRRC15 mRNA level while suppressing SCG5 mRNA expression. Samrotamab can be used for synthesis of ADC ABBV-085[1][2].
Product Specifications
CAS Number
2052591-32-7
Product Name Alternative
PR-1498487
UNSPSC
12352203
Target
ADC Antibody
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/samrotamab.html
Purity
98.26
Solubility
10 mM in DMSO
Smiles
[Samrotamab]
Molecular Weight
(145.92 kDa)
References & Citations
[1]Dong SW, et al. The role of LRRC15-SCG5 in ECM protein binding as a prognostic signature for urothelial carcinoma. Am J Cancer Res. 2025 May 25;15 (5) :2301-2318. |[2]Demetri GD, et al. First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. Clin Cancer Res. 2021 Jul 1;27 (13) :3556-3566. |[3]Jonathan Gill and Richard Gorlick, dvancing therapy for osteosarcoma. Nat Rev Clin Oncol. 609–624 (2021) .
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC040966-100 1x 100 µL
Hepatocyte Specific (HepPar1), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC682550-500 1x 500 µL
NGF-Receptor (p75) / CD271 (Soft Tissue Tumor Marker) (NGFR/2550R), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details ![FITC Anti-Mouse CD4 Antibody[GK1.5]](https://cdn.genprice.uk/products/763/68dd14a1061270361e7d07ca/imageurl/e-ab-f1097c.webp)
BNC403141-500 1x 500 µL
SOX9 / SRY-box 9 (SOX9/3141R), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details